The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: The GIMEMA CML Working Party experience after a 7-year follow-up

Francesca Palandri, Fausto Castagnetti, Giuliana Alimena, Nicoletta Testoni, Massimo Breccia, Simona Luatti, Giovanna Rege-Cambrin, Fabio Stagno, Giorgina Specchia, Bruno Martino, Luciano Levato, Serena Merante, Anna Maria Liberati, Fabrizio Pane, Giuseppe Saglio, Daniele Alberti, Giovanni Martinelli, Michele Baccarani, Gianantonio Rosti

Research output: Contribution to journalArticle

Abstract

Background: Imatinib mesylate is the first line treatment for chronic myeloid leukemia. The advent of imatinib increased survival significantly in patients in an advanced phase of the disease. However, few long-term data on the outcome of these patients based on large, prospective and controlled trials are available. Design and Methods: A phase 2 multicenter trial of the use of imatinib 600 mg/daily in patients with accelerated phase chronic myeloid leukemia was sponsored and promoted by the Italian Cooperative Study Group on Chronic Myeloid Leukemia in 2001. Results: One hundred and eleven patients were enrolled; the median follow-up of the 41 living patients is 82 months (range, 73-87). One hundred and seven patients (96%) returned to chronic phase and 79 patients (71%) achieved a complete hematologic response. Cumulative best rates of major cytogenetic response and complete cytogenetic response were 30% and 21%, respectively. All responses were maintained for a minimum of 4 weeks. At last follow-up, four patients were alive in complete remission after allogeneic transplant, 16 patients (14%) had switched to a second generation tyrosine kinase inhibitor and 21 patients (19%) were alive on imatinib therapy. No late toxicities were observed. Progression-free survival and event-free survival rates were 36.5% and 15%, respectively, at 7 years. The median survival time was 37 months, and was significantly associated with the achievement of a complete hematologic response or a complete cytogenetic response. Conclusions: Imatinib may induce durable responses, associated with prolonged survival, in patients with accelerated phase chronic myeloid leukemia (clinicaltrials.gov identifier: NCT00514969).

Original languageEnglish
Pages (from-to)205-212
Number of pages8
JournalHaematologica
Volume94
Issue number2
DOIs
Publication statusPublished - Feb 2009

Fingerprint

Leukemia, Myeloid, Accelerated Phase
Cytogenetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Disease-Free Survival
Survival
Imatinib Mesylate

Keywords

  • Accelerated phase
  • Chronic myeloid leukemia
  • Imatinib
  • Long-term results

ASJC Scopus subject areas

  • Hematology

Cite this

The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg : The GIMEMA CML Working Party experience after a 7-year follow-up. / Palandri, Francesca; Castagnetti, Fausto; Alimena, Giuliana; Testoni, Nicoletta; Breccia, Massimo; Luatti, Simona; Rege-Cambrin, Giovanna; Stagno, Fabio; Specchia, Giorgina; Martino, Bruno; Levato, Luciano; Merante, Serena; Liberati, Anna Maria; Pane, Fabrizio; Saglio, Giuseppe; Alberti, Daniele; Martinelli, Giovanni; Baccarani, Michele; Rosti, Gianantonio.

In: Haematologica, Vol. 94, No. 2, 02.2009, p. 205-212.

Research output: Contribution to journalArticle

Palandri, F, Castagnetti, F, Alimena, G, Testoni, N, Breccia, M, Luatti, S, Rege-Cambrin, G, Stagno, F, Specchia, G, Martino, B, Levato, L, Merante, S, Liberati, AM, Pane, F, Saglio, G, Alberti, D, Martinelli, G, Baccarani, M & Rosti, G 2009, 'The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: The GIMEMA CML Working Party experience after a 7-year follow-up', Haematologica, vol. 94, no. 2, pp. 205-212. https://doi.org/10.3324/haematol.13529
Palandri, Francesca ; Castagnetti, Fausto ; Alimena, Giuliana ; Testoni, Nicoletta ; Breccia, Massimo ; Luatti, Simona ; Rege-Cambrin, Giovanna ; Stagno, Fabio ; Specchia, Giorgina ; Martino, Bruno ; Levato, Luciano ; Merante, Serena ; Liberati, Anna Maria ; Pane, Fabrizio ; Saglio, Giuseppe ; Alberti, Daniele ; Martinelli, Giovanni ; Baccarani, Michele ; Rosti, Gianantonio. / The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg : The GIMEMA CML Working Party experience after a 7-year follow-up. In: Haematologica. 2009 ; Vol. 94, No. 2. pp. 205-212.
@article{cfeb8ad040e04902ab58776fd9a245a8,
title = "The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: The GIMEMA CML Working Party experience after a 7-year follow-up",
abstract = "Background: Imatinib mesylate is the first line treatment for chronic myeloid leukemia. The advent of imatinib increased survival significantly in patients in an advanced phase of the disease. However, few long-term data on the outcome of these patients based on large, prospective and controlled trials are available. Design and Methods: A phase 2 multicenter trial of the use of imatinib 600 mg/daily in patients with accelerated phase chronic myeloid leukemia was sponsored and promoted by the Italian Cooperative Study Group on Chronic Myeloid Leukemia in 2001. Results: One hundred and eleven patients were enrolled; the median follow-up of the 41 living patients is 82 months (range, 73-87). One hundred and seven patients (96{\%}) returned to chronic phase and 79 patients (71{\%}) achieved a complete hematologic response. Cumulative best rates of major cytogenetic response and complete cytogenetic response were 30{\%} and 21{\%}, respectively. All responses were maintained for a minimum of 4 weeks. At last follow-up, four patients were alive in complete remission after allogeneic transplant, 16 patients (14{\%}) had switched to a second generation tyrosine kinase inhibitor and 21 patients (19{\%}) were alive on imatinib therapy. No late toxicities were observed. Progression-free survival and event-free survival rates were 36.5{\%} and 15{\%}, respectively, at 7 years. The median survival time was 37 months, and was significantly associated with the achievement of a complete hematologic response or a complete cytogenetic response. Conclusions: Imatinib may induce durable responses, associated with prolonged survival, in patients with accelerated phase chronic myeloid leukemia (clinicaltrials.gov identifier: NCT00514969).",
keywords = "Accelerated phase, Chronic myeloid leukemia, Imatinib, Long-term results",
author = "Francesca Palandri and Fausto Castagnetti and Giuliana Alimena and Nicoletta Testoni and Massimo Breccia and Simona Luatti and Giovanna Rege-Cambrin and Fabio Stagno and Giorgina Specchia and Bruno Martino and Luciano Levato and Serena Merante and Liberati, {Anna Maria} and Fabrizio Pane and Giuseppe Saglio and Daniele Alberti and Giovanni Martinelli and Michele Baccarani and Gianantonio Rosti",
year = "2009",
month = "2",
doi = "10.3324/haematol.13529",
language = "English",
volume = "94",
pages = "205--212",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "2",

}

TY - JOUR

T1 - The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg

T2 - The GIMEMA CML Working Party experience after a 7-year follow-up

AU - Palandri, Francesca

AU - Castagnetti, Fausto

AU - Alimena, Giuliana

AU - Testoni, Nicoletta

AU - Breccia, Massimo

AU - Luatti, Simona

AU - Rege-Cambrin, Giovanna

AU - Stagno, Fabio

AU - Specchia, Giorgina

AU - Martino, Bruno

AU - Levato, Luciano

AU - Merante, Serena

AU - Liberati, Anna Maria

AU - Pane, Fabrizio

AU - Saglio, Giuseppe

AU - Alberti, Daniele

AU - Martinelli, Giovanni

AU - Baccarani, Michele

AU - Rosti, Gianantonio

PY - 2009/2

Y1 - 2009/2

N2 - Background: Imatinib mesylate is the first line treatment for chronic myeloid leukemia. The advent of imatinib increased survival significantly in patients in an advanced phase of the disease. However, few long-term data on the outcome of these patients based on large, prospective and controlled trials are available. Design and Methods: A phase 2 multicenter trial of the use of imatinib 600 mg/daily in patients with accelerated phase chronic myeloid leukemia was sponsored and promoted by the Italian Cooperative Study Group on Chronic Myeloid Leukemia in 2001. Results: One hundred and eleven patients were enrolled; the median follow-up of the 41 living patients is 82 months (range, 73-87). One hundred and seven patients (96%) returned to chronic phase and 79 patients (71%) achieved a complete hematologic response. Cumulative best rates of major cytogenetic response and complete cytogenetic response were 30% and 21%, respectively. All responses were maintained for a minimum of 4 weeks. At last follow-up, four patients were alive in complete remission after allogeneic transplant, 16 patients (14%) had switched to a second generation tyrosine kinase inhibitor and 21 patients (19%) were alive on imatinib therapy. No late toxicities were observed. Progression-free survival and event-free survival rates were 36.5% and 15%, respectively, at 7 years. The median survival time was 37 months, and was significantly associated with the achievement of a complete hematologic response or a complete cytogenetic response. Conclusions: Imatinib may induce durable responses, associated with prolonged survival, in patients with accelerated phase chronic myeloid leukemia (clinicaltrials.gov identifier: NCT00514969).

AB - Background: Imatinib mesylate is the first line treatment for chronic myeloid leukemia. The advent of imatinib increased survival significantly in patients in an advanced phase of the disease. However, few long-term data on the outcome of these patients based on large, prospective and controlled trials are available. Design and Methods: A phase 2 multicenter trial of the use of imatinib 600 mg/daily in patients with accelerated phase chronic myeloid leukemia was sponsored and promoted by the Italian Cooperative Study Group on Chronic Myeloid Leukemia in 2001. Results: One hundred and eleven patients were enrolled; the median follow-up of the 41 living patients is 82 months (range, 73-87). One hundred and seven patients (96%) returned to chronic phase and 79 patients (71%) achieved a complete hematologic response. Cumulative best rates of major cytogenetic response and complete cytogenetic response were 30% and 21%, respectively. All responses were maintained for a minimum of 4 weeks. At last follow-up, four patients were alive in complete remission after allogeneic transplant, 16 patients (14%) had switched to a second generation tyrosine kinase inhibitor and 21 patients (19%) were alive on imatinib therapy. No late toxicities were observed. Progression-free survival and event-free survival rates were 36.5% and 15%, respectively, at 7 years. The median survival time was 37 months, and was significantly associated with the achievement of a complete hematologic response or a complete cytogenetic response. Conclusions: Imatinib may induce durable responses, associated with prolonged survival, in patients with accelerated phase chronic myeloid leukemia (clinicaltrials.gov identifier: NCT00514969).

KW - Accelerated phase

KW - Chronic myeloid leukemia

KW - Imatinib

KW - Long-term results

UR - http://www.scopus.com/inward/record.url?scp=59549084574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59549084574&partnerID=8YFLogxK

U2 - 10.3324/haematol.13529

DO - 10.3324/haematol.13529

M3 - Article

C2 - 19144656

AN - SCOPUS:59549084574

VL - 94

SP - 205

EP - 212

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 2

ER -